Boule reports Q3 sales decline amid instrument supply challenges
Revenue fell 24.4% year over year as instrument sales dropped; consumables and OEM remained stable, while the company evaluates measures to strengthen its financial position.
See the latest news and media coverage for Boule. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global hematology diagnostics solutions provider
boule.comLast updated
In short: Boule posted a 24.4% Q3 2026 sales decline and named Johan Folkunger CEO.
Revenue fell 24.4% year over year as instrument sales dropped; consumables and OEM remained stable, while the company evaluates measures to strengthen its financial position.
The decision was made at the extraordinary general meeting and ensures capital injection through AB Grenspecialisten according to the board's proposal.
An extraordinary general meeting will be held on 31 August to decide on approval of a loan from AB Grenspecialisten.
Adjusted operating profit decreased to MSEK 3.3, affected by geopolitical disturbance and new CEO took office.
Challenges in the instrument business but good stability in sales of consumables and the OEM business Quarter July-September 2026Net sales amounted to SEK 96.2 million...
17/07 Boule Diagnostics AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026 CI 17/07 Bourse de...
The diagnostics company Boule Diagnostics decreased revenue in the second quarter but also reduced the net loss, while the operating result became...
Boule Diagnostics AB ( (SE:BOUL) ) just unveiled an announcement.
Track Boule and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boule and other trending companies.